Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eiko LifesciencesBOM:540204 -0.43%70 PS Ratio is 1.32 as of Aug. 03, 2026, which is 43% below its 10-year median of 2.33. GuruFocus rates BOM:540204 with a GF Score™ of 70/100 and a GF Value™ of ₹79.93 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 1,576 Chemicals companies, Eiko Lifesciences ranks better than 52.92% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Eiko Lifesciences's share price is ₹48.78.
Eiko Lifesciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹37.07. Hence, Eiko Lifesciences's PS Ratio for today is 1.32.
Good Sign:
Eiko Lifesciences Ltd stock PS Ratio (=1.31) is close to 3-year low of 1.31.
The historical rank and industry rank for Eiko Lifesciences's PS Ratio or its related term are showing as below:
BOM:540204'
s PS Ratio Range Over the Past 10 Years
Min: 0.47 Med: 2.33 Max: 185.71
Current: 1.32
During the past 13 years, Eiko Lifesciences's highest PS Ratio was 185.71. The lowest was 0.47. And the median was 2.33.
BOM:540204's PS Ratio is ranked better than 52.92% of 1576
companies
in the Chemicals industry
Industry Median: 1.4
vs BOM:540204: 1.32
During the past 12 months, the average Revenue per Share Growth Rate of Eiko Lifesciences was 29.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 25.90% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 6.00% per year.
During the past 13 years, Eiko Lifesciences's highest 3-Year average Revenue per Share Growth Rate was 81.70% per year. The lowest was -35.70% per year. And the median was 25.90% per year.
Eiko Lifesciences (BOM:540204) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Eiko Lifesciences PS Ratio Related Terms
Eiko Lifesciences PS Ratio Historical Data
* Premium members only.
The historical data trend for Eiko Lifesciences's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Specialty Chemicals subindustry, Eiko Lifesciences's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eiko Lifesciences PS Ratio vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Eiko Lifesciences's PS Ratio distribution charts can be found below:
* The bar in red indicates where Eiko Lifesciences's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Eiko Lifesciences's Share Price of today is ₹48.78. Eiko Lifesciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹37.07.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Eiko Lifesciences (BOM:540204) has a PS Ratio of 1.32 as of Aug. 03, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Eiko Lifesciences and its competitors. This is 43% below median its historical median of 2.33. Over the past decade, Eiko Lifesciences' PS Ratio has ranged from 0.47 to 185.71. According to the industry distribution chart, Eiko Lifesciences ranks #742 out of 1576 companies in the Chemicals industry, placing it in the top 47.1%.
Is Eiko Lifesciences' PS Ratio too high?
Eiko Lifesciences' current PS Ratio of 1.32 is 43% below median its 10-year median of 2.33. Over the past 10 years, this metric has ranged from a low of 0.47 to a high of 185.71. The Chemicals industry median PS Ratio is 1.40. Eiko Lifesciences' value of 1.32 is 5.7% below this industry median. Based on the distribution chart, Eiko Lifesciences ranks #742 out of 1576 companies in the Chemicals industry, which is above the industry midpoint. Overall, Eiko Lifesciences has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eiko Lifesciences' PS Ratio compare to LIN and SHW?
According to the Chemicals industry distribution chart, Eiko Lifesciences ranks #742 out of 1576 companies for PS Ratio. This puts Eiko Lifesciences in the upper half of its industry. The industry median PS Ratio is 1.40. Eiko Lifesciences' value of 1.32 is 5.7% below this benchmark. Historically, Eiko Lifesciences' own PS Ratio has ranged from 0.47 to 185.71 over the past decade. While the company's 10-year median is 2.33 vs. the industry median of 1.40, Eiko Lifesciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Chemicals company?
The median PS Ratio among Chemicals companies is 1.40, based on 1,576 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eiko Lifesciences's current PS Ratio of 1.32 is 5.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Eiko Lifesciences and its competitors. For the Chemicals industry, the median PS Ratio is 1.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eiko Lifesciences's current PS Ratio is 1.32, which is 43% below median its own 10-year median of 2.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eiko Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Eiko Lifesciences (BOM:540204) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹79.93, compared to a current price of ₹48.78 — trading 39% below its estimated fair value. The current PS Ratio is 1.32, which is 43% below median its 10-year median of 2.33 and 5.7% below the Chemicals industry median of 1.40. Eiko Lifesciences' overall GF Score™ is 70/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Eiko Lifesciences (BOM:540204), the current PS Ratio is 1.32 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eiko Lifesciences (BOM:540204) Overvalued in 2026?
Based on GuruFocus' analysis, Eiko Lifesciences stock appears to be undervalued.
The current stock price of ₹48.78 is trading 39% below its estimated GF Value™ of ₹79.93.
GuruFocus considers Eiko Lifesciences to be Significantly Undervalued.
Key valuation signals for BOM:540204:
PS Ratio: 1.32 (43% below median its 10-year median of 2.33)
GF Value™: ₹79.93 vs. price of ₹48.78 (39% below fair value)
Industry Position: 5.7% below the Chemicals median (#742 of 1576)
No single metric tells the full story. See the BOM:540204 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eiko Lifesciences Ltd is a manufacturer, supplier, and exporter of specialty chemicals, fine chemicals, and pharma intermediates.. The company's segment includes Agrochemicals, Oleo Chemicals, Pharmaceuticals, Food Additives, clinical research, development, and Logistics. Geographically, the company generates the majority of its revenue from the Domestic market.
70GF Score
Get the complete analysis for BOM:540204
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540204 has been successfully added to your 
